By William Gullotti
Buffalo, N.Y., Aug. 10 – UBS AG London Branch priced $500,000 of buffer autocallable contingent yield notes due May 21, 2026 linked to the lesser performing of the ARK Genomic Revolution ETF and the ARK Innovation ETF, according to a 424B2 filing with the Securities and Exchange Commission.
The notes will pay a contingent monthly coupon at an annual rate of 12% if each ETF closes at or above its 70% coupon barrier on the review date for that quarter.
The notes will be called at par plus coupon if each ETF closes at or above its initial level on any monthly review date after one year.
The payout at maturity will be par unless either ETF finishes below its 80% buffer level, in which case investors will be exposed to any losses of the worse performing ETF beyond 20%.
UBS Securities LLC and UBS Investment Bank are the agents.
Issuer: | UBS AG, London Branch
|
Issue: | Buffer autocallable contingent yield notes
|
Underlying ETFs: | ARK Genomic Revolution ETF and ARK Innovation ETF
|
Amount: | $500,000
|
Maturity: | May 21, 2026
|
Coupon: | 12% annual, payable monthly if each ETF closes at or above coupon barrier on observation date
|
Price: | Par
|
Call: | Notes will be called at par plus coupon if each ETF closes at or above its initial level on any monthly review date after one year
|
Payout at maturity: | Par unless either ETF closes below buffer level, in which case 1% loss for each 1% decline of lesser performing ETF beyond buffer
|
Initial level: | $77.90 for Genomic, $104.79 for Innovation
|
Coupon barrier levels: | $54.53 for Genomic, $73.35 for Innovation; 70% of initial levels
|
Buffer level: | $62.32 for Genomic, $83.83 for Innovation; 80% of initial levels
|
Pricing date: | May 18
|
Settlement date: | May 21
|
Agents: | UBS Financial Services Inc. and UBS Investment Bank
|
Fees: | 0.75%
|
Cusip: | 90276BH55
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.